| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |



From the Department of Pathology,
*
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Northern California Cancer Center,
Union City, California; University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System,
Little Rock, Arkansas; and the Department of Microbiology and Immunology,
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Epstein-Barr Virus (EBV) infects nearly all humans and then persists for the life of the host. In some people who later develop cancer, EBV DNA is present within malignant cells and circulates at elevated levels in the plasma. In the current study, we validated five novel quantitative polymerase chain reaction (Q-PCR) assays targeting disparate but highly conserved segments of the EBV genome (BamH1W, EBNA1, LMP1, LMP2, and BZLF1). Each assay was sensitive to as few as 50 copies of EBV DNA per reaction and was linear across at least four orders of magnitude. When applied to paraffin-embedded tissues in concert with EBV-encoded RNA (EBER) in situ hybridization, the BamH1W and EBNA1 assays were the most informative, while use of the entire battery of EBV PCR assays may help identify genomic polymorphisms or deletions. Higher viral loads were found in the 17 EBER-positive compared with the 13 EBER-negative tumors (means 84,978 versus 22 copies of EBV per 100,000 cells, respectively). The five Q-PCR assays were also informative in plasma samples where EBV was measurable in all nine patients with lymphoma or infectious mononucleosis, whereas EBV was undetectable in all nine healthy controls. The findings suggest that Q-PCR is an effective method of distinguishing disease-associated virus from incidental virus in paraffin-embedded tissue and in plasma samples.
This article has been cited by other articles:
![]() |
M. L. Gulley and W. Tang Laboratory Assays for Epstein-Barr Virus-Related Disease J. Mol. Diagn., July 1, 2008; 10(4): 279 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Navarro, A. Gaya, A. Martinez, A. Urbano-Ispizua, A. Pons, O. Balague, B. Gel, P. Abrisqueta, A. Lopez-Guillermo, R. Artells, et al. MicroRNA expression profiling in classic Hodgkin lymphoma Blood, March 1, 2008; 111(5): 2825 - 2832. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-F. Chiu, C.-P. Tung, Y.-H. Lee, W.-H. Wang, C. Li, J.-Y. Hung, C.-Y. Wang, Y. Kawaguchi, and S.-T. Liu A comprehensive library of mutations of Epstein Barr virus J. Gen. Virol., September 1, 2007; 88(9): 2463 - 2472. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tugizov, R. Herrera, P. Veluppillai, J. Greenspan, D. Greenspan, and J. M. Palefsky Epstein-Barr Virus (EBV)-Infected Monocytes Facilitate Dissemination of EBV within the Oral Mucosal Epithelium J. Virol., June 1, 2007; 81(11): 5484 - 5496. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Gulley, H. Fan, and S. H. Elmore Validation of Roche LightCycler Epstein-Barr Virus Quantification Reagents in a Clinical Laboratory Setting J. Mol. Diagn., November 1, 2006; 8(5): 589 - 597. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |